Staidson (Beijing) Biopharmaceuticals Co (SZSE:300204) Days Sales Outstanding : 53.37 (As of Mar. 2024)

View and export this data going back to 2011. Start your Free Trial

What is Staidson (Beijing) Biopharmaceuticals Co Days Sales Outstanding?

Staidson (Beijing) Biopharmaceuticals Co's average Accounts Receivable for the three months ended in Mar. 2024 was ¥55.6 Mil. Staidson (Beijing) Biopharmaceuticals Co's Revenue for the three months ended in Mar. 2024 was ¥95.0 Mil. Hence, Staidson (Beijing) Biopharmaceuticals Co's Days Sales Outstanding for the three months ended in Mar. 2024 was 53.37.

The historical rank and industry rank for Staidson (Beijing) Biopharmaceuticals Co's Days Sales Outstanding or its related term are showing as below:

SZSE:300204' s Days Sales Outstanding Range Over the Past 10 Years
Min: 60.85 Med: 66.51 Max: 105.46
Current: 69.6

During the past 13 years, Staidson (Beijing) Biopharmaceuticals Co's highest Days Sales Outstanding was 105.46. The lowest was 60.85. And the median was 66.51.

SZSE:300204's Days Sales Outstanding is ranked better than
52.28% of 878 companies
in the Biotechnology industry
Industry Median: 72.84 vs SZSE:300204: 69.60

Staidson (Beijing) Biopharmaceuticals Co's Days Sales Outstanding declined from Mar. 2023 (180.64) to Mar. 2024 (53.37).

Staidson (Beijing) Biopharmaceuticals Co Days Sales Outstanding Historical Data

The historical data trend for Staidson (Beijing) Biopharmaceuticals Co's Days Sales Outstanding can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Staidson (Beijing) Biopharmaceuticals Co Days Sales Outstanding Chart

Staidson (Beijing) Biopharmaceuticals Co Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Days Sales Outstanding

Get a 7-Day Free Trial

60.85

83.06

65.66

90.19

105.46

Staidson (Beijing) Biopharmaceuticals Co Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Days Sales Outstanding	Get a 7-Day Free Trial															180.64	84.99	69.22	65.38	53.37

Competitive Comparison of Staidson (Beijing) Biopharmaceuticals Co's Days Sales Outstanding

For the Biotechnology subindustry, Staidson (Beijing) Biopharmaceuticals Co's Days Sales Outstanding, along with its competitors' market caps and Days Sales Outstanding data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Staidson (Beijing) Biopharmaceuticals Co's Days Sales Outstanding Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Staidson (Beijing) Biopharmaceuticals Co's Days Sales Outstanding distribution charts can be found below:

* The bar in red indicates where Staidson (Beijing) Biopharmaceuticals Co's Days Sales Outstanding falls into.

Staidson (Beijing) Biopharmaceuticals Co Days Sales Outstanding Calculation

Days Sales Outstanding measures the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Accounts Receivable can be measured by Days Sales Outstanding.

Staidson (Beijing) Biopharmaceuticals Co's Days Sales Outstanding for the fiscal year that ended in Dec. 2023 is calculated as

	Days Sales Outstanding (A: Dec. 2023 )
=	Average Accounts Receivable					/	Revenue	*	Days in Period
=	( (Accounts Receivable (A: Dec. 2022 )	+	Accounts Receivable (A: Dec. 2023 ))	/	count )	/	Revenue (A: Dec. 2023 )	*	Days in Period
=	( (152.176	+	58.265)	/	2 )	/	364.175	*	365
=	105.2205					/	364.175	*	365
=	105.46

Staidson (Beijing) Biopharmaceuticals Co's Days Sales Outstanding for the quarter that ended in Mar. 2024 is calculated as:

	Days Sales Outstanding (Q: Mar. 2024 )
=	Average Accounts Receivable					/	Revenue	*	Days in Period
=	( (Accounts Receivable (A: Dec. 2023 )	+	Accounts Receivable (A: Mar. 2024 ))	/	count )	/	Revenue (A: Mar. 2024 )	*	Days in Period
=	( (58.265	+	52.841)	/	2 )	/	94.983	*	365 / 4
=	55.553					/	94.983	*	365 / 4
=	53.37

Staidson (Beijing) Biopharmaceuticals Co (SZSE:300204) Days Sales Outstanding Explanation

For retailers, when we compare Days Sales Outstanding, it is important to compare the same period in the previous years.

Staidson (Beijing) Biopharmaceuticals Co Days Sales Outstanding Related Terms

Thank you for viewing the detailed overview of Staidson (Beijing) Biopharmaceuticals Co's Days Sales Outstanding provided by GuruFocus.com. Please click on the following links to see related term pages.

Staidson (Beijing) Biopharmaceuticals Co (SZSE:300204) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Staidson (Beijing) Biopharmaceuticals Co Ltd (SZSE:300204) » Definitions » Days Sales Outstanding

Comparable Companies

Traded in Other Exchanges

N/A

Address

Rongjing Dong Street, No 5 Beijing Economic and Technological Development Zone, Beijing, CHN, 100176

Website

http://www.staidson.com

Staidson (Beijing) Biopharmaceuticals Co Ltd is a pharmaceutical company mainly engaged in the research, development, production, and sale of biological products in China. Its products include mouse nerve growth factor injection, intravenous compound polyethylene glycol electrolyte powder solution, gliclazide, nabumetone, and aspirin.

Executives

Zhang Hong Shan	Supervisors
Zheng Hong	Supervisors
Cheng Jiang Hong	Executives
Feng Yu Jing	Executives
Ma Li Na	Secretary, Director
Zhou Zhi Wen	Director
Wang Huan	Securities Affairs Representative
Zhang Rong Qin	Executives
Xu Jiang Ping	Executives
Cao Hai Yan	Supervisors
Sun Yan Fang	Executives
Jiang Li Xin	Director
Gu Jian Ping	Director
Xu Xiang Qing	Supervisors
Gu Zhen Qi	Director

Staidson (Beijing) Biopharmaceuticals Co (SZSE:300204) Headlines

No Headlines